IL1B and asthma: These results and others pointing to the potential efficacy of targeting IL1β have led to the development of alternative agents such as rilonacept (IL1 trap) (175) and canakinumab (anti-IL1β antibody) (176) that could also be potential tools for IL1β modulation in asthma.